The Journal of Immunology, 1998, 160: 5790-5796.
Copyright © 1998 by The American Association of Immunologists
Differential Involvement of a Fas-CPP32-Like Protease Pathway in Apoptosis of TCR/CD9-Costimulated, Naive T Cells and TCR-Restimulated, Activated T Cells1
Cheung-Seog Park*,
Yumi Yashiro*,
Xu-Guang Tai*,
Kazuhito Toyo-oka*,
Toshiyuki Hamaoka*,
Hideo Yagita
,
Ko Okumura
,
Steven Neben
and
Hiromi Fujiwara2,*
*
Biomedical Research Center, Osaka University Medical School, Osaka, Japan;
Juntendo University School of Medicine, Tokyo, Japan; and
Genetics Institute, Cambridge, MA 02140
 |
Abstract
|
|---|
Our previous study showed that CD9 costimulation of TCR-triggered
naive T cells elicits activation ([3H]TdR
incorporation) that is similar to CD28 costimulation; however, unlike
CD28 costimulation, CD9 costimulation results in apoptosis of these
previously activated T cells. Here, we investigated whether the
apoptosis occurring after TCR/CD9 stimulation is associated with a
death pathway involving Fas stimulation and Fas-mediated caspase
activation as observed in activation-induced cell death (AICD). In
contrast to AICD, the apoptosis resulting from TCR/CD9 stimulation in
C57BL/6 T cells was independent of Fas, because this form of apoptosis
was not prevented by anti-Fas ligand mAb and was also induced in
MRL/lpr T cells. AICD was observed at 12 h after the
restimulation of activated T cells with anti-CD3 and reached a peak
level at 24 h after this restimulation. CPP32-like protease
activity was detected during AICD. Although TCR/CD9
stimulation-associated apoptosis was observed at 24 h after the
stimulation of naive T cells and reached a peak level at 36 h
after this stimulation, CPP32-like protease activity in these T cells
was only marginal at all time points. Nevertheless, both forms of
apoptosis were prevented similarly by two different peptide-based
caspase inhibitors. These results indicate that the apoptosis that
follows the T cell activation which is induced as a result of CD9
costimulation does not involve a Fas-CPP32-like protease pathway, but
suggest that different caspase members are likely to be critical in
this form of apoptosis.
 |
Introduction
|
|---|
Lymphocyte
death plays
an important role in controlling immune responses. Because such cell
deaths are associated with apoptotic features, it has been commonly
assumed that they share a common core of intracellular biochemical
steps which lead to death, even though the triggering receptors may
differ. Numerous studies have implicated members of the caspase family
as key participants in apoptotic cell death (1, 2, 3). Evidence that this
family of proteases are part of a core apoptotic pathway comes largely
from studies showing that the inhibitors of these proteases block a
wide range of apoptotic death systems (1). Among the caspase family
members, CPP32 (caspase-3) appears to play a major role in apoptosis,
for the following reasons: 1) CPP32 is processed into active subunits
in cells receiving various apoptosis-inducing stimuli (4, 5, 6, 7, 8), and 2)
CPP32 accounts for the proteolytic activity that is responsible for the
cleavage of potential substrates at the onset of apoptosis (9, 10, 11, 12).
Apoptosis due to the absence of necessary survival signals is a
universal property of almost all cells (13). However, T cells are
uniquely capable of undergoing another form of apoptotic death, called
activation-induced cell death
(AICD).3 AICD occurs as
a result of repeated TCR stimulation (14, 15, 16) and is due to the
coexpression of Fas and Fas ligand (FasL) (17, 18, 19). Moreover, the
caspase family members, especially CPP32-like protease, are thought to
be involved in Fas-mediated apoptosis, implying that AICD uses a common
apoptotic pathway which leads to CPP32 activation (5, 6, 20). In
addition to AICD, various forms of apoptosis occur in T cells,
including a Fas-independent form of apoptosis (21, 22). We have
recently shown that CD9 costimulation of TCR-triggered naive T cells
induces as potent an activation (measured by [3H]TdR
incorporation) as CD28 costimulation (23); however, the TCR/CD9
stimulation-induced activation is followed immediately by the apoptosis
of previously activated T cells (24). It remains to be determined
whether this form of apoptosis involves a Fas-CPP32 apoptotic
pathway.
In this study, we investigated whether Fas stimulation and/or CPP32
activation are involved in the apoptosis of naive T cells that occurs
when TCR is stimulated in combination with the costimulation of CD9 as
a non-CD28 costimulatory molecule. The results indicated that in
contrast to AICD, TCR/CD9 costimulation-associated apoptosis is
independent of Fas, and CPP32 activation is hardly observed even at the
time point when high proportions of cells are rendered apoptotic.
Nevertheless, this form of apoptosis was prevented by two different
peptide-fluoromethyl ketone (FMK) reagents. These FMK reagents were
capable of blocking the activity of the caspase family, including the
IL-1ß-converting enzyme (ICE) and CPP32. These results indicate that
unlike apoptosis in AICD, neither Fas nor CPP32-like protease(s) are
involved in the apoptosis following T cell activation which is induced
upon inappropriate costimulation; however different caspase members are
likely to be activated in such T cells.
 |
Materials and Methods
|
|---|
Mice
Female C57BL/6 (B6), MRL/MpJ-lpr/lpr
(MRL/lpr) and control MRL/MpJ-+/+ (MRL/+) mice were
purchased from the Shizuoka Laboratory Animal Center (Hamamatsu, Japan)
and used at 5 to 7 wk of age.
Reagents
The following reagents were used: Anti-CD3 (145-2C11) (25),
anti-CD9 (9D3) (23), anti-FasL (K10) (26), and
anti-I-Ad/b (34-5-3S) (27) mAbs were purified from
culture supernatants or from the ascitic fluids of hybridomas producing
the relevant mAb. Anti-Fas mAb (RMF6) was purchased from MBL
International (Watertown, MA), and anti-TNF mAb and anti-TNF
antiserum were obtained from Genzyme (Cambridge, MA). Rat and mouse
control IgG were purchased from Biomedia (Foster City, CA) and Jackson
ImmunoResearch Labs (West Grove, PA), respectively. Normal rabbit serum
was obtained from the Shizuoka Laboratory Animal Center. The ICE family
protease (caspase) inhibitors Cbz-Val-Ala-Asp-(OMe)-FMK (Z-VAD-FMK) and
Boc-Asp-(OMe)-FMK (BD-FMK) as well as the control reagent
Cbz-Phe-Ala-FMK (ZFA-FMK) were purchased from Enzyme System Products
(Dublin, CA). These reagents were dissolved as stock solutions of 50 mM
in DMSO and stored at -80°C. The CPP32 fluorescent substrate
(7-methoxycoumarin-4-yl)-acetyl (MCA)-Asp-Glu-Val-Asp-Ala-Pro-Lys-DNP
(MCA-DEVDAPK-DNP) was purchased from Peptide Institute (Osaka, Japan).
N-acetyl-L-cysteine (NAC) and Con A were
purchased from Sigma (St. Louis, Mo).
Preparation of a purified T cell population
Lymph node cells were depleted of B cells and
Ia+ APCs by immunomagnetic negative selection as
previously described (28). Briefly, Ia+ APCs in a lymph
node cell population were allowed to react with the
anti-I-Ad/b mAb. The lymph node cells containing these
labeled cells and surface Ig+ cells (B cells) were
incubated with magnetic particles that had been conjugated to goat
anti-mouse IgG (Advanced Magnetic, Cambridge, MA). Surface
Ig- and Ia- cells (B cell- and APC-depleted
populations) were obtained by removing cell-bound magnetic particles
with a rare earth magnet (Advanced Magnetic). The purity of the
resulting population was verified by flow cytometry with
anti-CD3. Purified T cells were consistently >98%
CD3+.
Primary T cell stimulation culture system and culture system of
AICD
mAbs were diluted to 1 µg/ml (anti-CD3) or 10 µg/ml
(anti-CD9 or anti-CD28) in PBS unless otherwise indicated and
then immobilized to the individual wells of 24-well culture plates
(Corning 25860, Corning Glass Works, Corning, NY) in a final volume of
0.5 ml. After 3 h, solutions were discarded, and plates were
washed twice with PBS. Purified T cells were cultured in 1 ml of RPMI
1640 medium supplemented with 10% FBS and 5 x
10-5 2-ME at a concentration of 2.0 x
106 cells/well in mAb-immobilized 24-well culture plates in
a humidified atmosphere at 5% CO2 at 37°C for various
days. For the AICD system, lymph node cells (2 x 106)
were initially stimulated with 2 µg/ml Con A in 24-well culture
plates in a final volume of 1 ml for 48 h, washed with RPMI 1640
medium containing 10 mg/ml
-methylmannoside, and incubated in RPMI
1640 medium containing FBS, 2-ME, and 50 U/ml rIL-2 for another 48
h to create predisposition to apoptosis as previously described (29).
The cells were then stimulated with plate-bound anti-CD3
(immobilized with 1 µg/ml anti-CD3) and subjected to the
measurement of apoptosis and the assay for CPP32-like protease
activity.
Assay for CPP32-like protease activity
CPP32-like protease activity in the cell lysates was determined
using the fluorescent substrate, MCA-DEVDAPK-DNP, as previously
described (5). Briefly, cytosolic extracts were prepared by repeatedly
freezing and thawing the cells in 100 µl extraction buffer containing
50 mM PIPES-NaOH (pH 7.0), 50 mM KCl, 5 mM EDTA, 2 mM
MgCl2, 1 mM DTT, 1 mM PMSF, 10 µg/ml leupeptin, and
10 µg/ml aprotinin. Cell lysates (510 µg) were diluted with
reaction buffer (100 mM HEPES-KOH buffer (pH 7.5), 10% sucrose, 0.1%
3-([3-cholamidopropyl]dimethylammonio)-1-propanesulfonate, and 10 mM
DTT), and incubated at 30°C for 60 min with 1 µM fluorescent
substrate. The fluorescence of the cleaved substrates was determined
using a spectrofluorometer that had been set at an excitation
wavelength of 328 nm and an emission wavelength of 393 nm, and the
enzyme activity was expressed in units: 1 U corresponds to the enzyme
activity that cleaves 100 pmol of the fluorescent substrate at 30°C
in 60 min.
Measurement of apoptosis
Apoptosis was examined as follows: cells were fixed and stained
with propidium iodide (PI), and apoptotic cells were quantitated by the
determination of the hypodiploid areas in the PI-staining profiles
which were used for cell cycle analysis (30). Apoptosis was also
determined by DNA fragmentation analysis after agarose gel
electrophoresis. T cells (5 x 105/sample) that
had been harvested after cultures were washed in PBS and lysed, and
their DNA was isolated as previously described (31). DNA was
electrophoresed in 2% agarose gels and stained with 0.1 µg/ml
ethidium bromide.
Immunofluorescence staining and flow cytometry
Cells (1 x 106) were incubated with
anti-Fas (RMF6) mAb. Anti-Fas-labeled cells were incubated with
biotinylated mouse anti-rat IgG (Jackson ImmunoResearch, West
Grove, PA) followed by RED670-conjugated streptavidin (Life
Technologies, Gaithersburg, MD). Cells were analyzed on a FACScalibur
(Becton Dickinson, San Jose, CA).
 |
Results
|
|---|
CD9-mediated costimulation of TCR-triggered naive T cells leads to
activation followed by apoptosis
Our previous studies have shown that CD9 costimulation of
TCR-triggered naive T cells elicits a potent activation of the T cells
that is similar to CD28 costimulation (23); however, this
costimulation, unlike CD28 costimulation, results in the apoptosis of
these previously activated T cells instead of proliferation (24). This
finding is indicated in Figure 1
.
Purified B6 T cells were cultured for 1 to 3 days in wells containing
anti-CD9 or anti-CD28 mAb that had been coimmobilized with a
suboptimal dose (0.25 µg/ml) of anti-CD3 mAb in the absence of
APCs (Fig. 1
A). The anti-CD9 mAb strikingly
increased the [3H]TdR uptake of T cells. The magnitude of
CD9 costimulation was significantly greater than CD28 costimulation
when evaluated on days 1 or 2. While CD28 costimulation exhibited a
progressive increase in [3H]TdR incorporation up to day 3
in culture, CD9 costimulation reached a peak response on day 2 and
exhibited a substantial decrease in [3H]TdR uptake on
day 3.

View larger version (22K):
[in this window]
[in a new window]
|
FIGURE 1. CD9-mediated costimulation of TCR-triggered naive T cells leads to
activation followed by apoptosis. A, Purified B6 resting
lymph node T cells (2 x 105/well) were cultured for 1
to 3 days in 96-well flat-bottom microplates that had been coated with
0.25 µg/ml anti-CD3 alone or in combination with 10 µg/ml
anti-CD9 or anti-CD28 mAb. Cells were pulse-labeled with 20
kBq/well of [3H]TdR for the final 8 h. B,
Purified T cells (2 x 106/well) were cultured in
24-well culture plates that had been coated with anti-CD3 (1
µg/ml) alone or in combination with anti-CD9 or anti-CD28 (10
µg/ml) for 2 days. Cells were harvested, fixed, and stained with PI
for cell cycle analysis. Both the proportion of hypodiploid (apoptotic)
cells in each group and the proportions of cells at the
G0/G1 and S/G2/M phases are
indicated.
|
|
A cell cycle analysis of T cells from the above three groups (Fig. 1
B) revealed that the content of the hypodiploid DNA
was high in T cells stimulated with anti-CD3 alone; in contrast, T
cells stimulated with anti-CD3 plus anti-CD28 displayed low
hypodiploid DNA content, and a significant proportion of these cells
were at the S/G2/M phases. Despite the induction of potent
[3H]TdR uptake, CD9 costimulation elicited only a slight
increase in the proportion of cells at the S/G2/M phases
compared with the increase observed in the costimulation-free group.
Instead, CD9 costimulation induced levels of apoptosis (induction of
cells with hypodiploid DNA) that were comparable with those in the
anti-CD3 alone group. Thus, the levels of proliferation did not
match with the cell cycle analysis data that we described previously
(24). Consistent with this, our previous study (24) showed that CD9
costimulation induced a decrease in viable cell recovery and an
increase in the dead cell number.
Apoptosis associated with TCR/CD9 costimulation is independent of
Fas
It is known that AICD is dependent upon the interaction between
Fas and FasL, both of which are expressed on activated T cells, and
that a Fas-mediated death signal is generated upon the restimulation of
these T cells with anti-CD3 (17, 18, 19). We first confirmed the expression
of Fas in TCR/CD9-costimulated T cells. The activated T cells used as
responders in AICD were prepared as previously described (29):
unfractionated B6 spleen cells were stimulated with 2 µg/ml Con A for
2 days, and cells were subsequently maintained with 50 U/ml rIL-2 for
an additional 2 days. These activated T cells and TCR/CD9-costimulated
T cells were stained with anti-Fas mAb. As shown in Figure 2
, both types of T cells express Fas.
However, although resting T cells expressed Fas, the levels of Fas on
resting T cells were slightly lower than those on activated T cells
(data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIGURE 2. Effect of NAC on the induction of Fas expression. Purified naive lymph
node T cells were stimulated with anti-CD3 (immobilized at 1
µg/ml) plus anti-CD9 (immobilized at 10 µg/ml) for 2 days in
the presence or absence of 25 mM NAC. Con A-stimulated lymph node T
cells were cultured for 2 days and subsequently stimulated with
immobilized anti-CD3 in the presence or absence of 25 mM NAC for 1
day. Cells were stained with 1 µg/ml anti-Fas mAb. A
TCR-restimulated, activated T cell population was gated for viable
cells. The results are representative of three similar
experiments.
|
|
We examined the effect of NAC, a thiol that is known to down-regulate
Fas expression, on the induction of Fas in TCR/CD9-costimulated or
activated T cells. When NAC was included during a 2-day maintenance
culture with rIL-2, Fas expression was down-regulated (data not shown).
The addition of NAC to a 1-day restimulation culture with immobilized
anti-CD3 also resulted in the down-regulation of Fas expression in
activated T cells (Fig. 2
), which is consistent with previous results
(32). Activated T cells restimulated with anti-CD3 in the absence
of NAC were rendered apoptotic (AICD), whereas AICD was largely
prevented when activated T cells were restimulated in the presence of
NAC (Fig. 3
). Fas expression was also
down-regulated in TCR/CD9-stimulated T cells by the addition of NAC
(Fig. 2
). Nevertheless, apoptosis in these T cells was only marginally
prevented, suggesting that this form of apoptosis is independent
of Fas.

View larger version (19K):
[in this window]
[in a new window]
|
FIGURE 3. NAC protects T cells from AICD but not from
TCR/CD9-costimulation-associated apoptosis. Portions of the same cells
that were used for the detection of Fas in Figure 2 were fixed and
stained with PI for cell cycle analysis. The proportion of hypodiploid
(apoptotic) cells is indicated. The results are representative of five
similar experiments.
|
|
To investigate the involvement of the Fas-FasL interaction in two types
of apoptosis more directly, we examined the effect of anti-FasL mAb
on the prevention of apoptosis. AICD was largely inhibited by
anti-FasL mAb, whereas anti-FasL mAb failed to inhibit
apoptosis in TCR/CD9-stimulated T cells (Fig. 4
). This was also the case with T cells
from MRL/+ mice (Fig. 5
). In T cells from
MRL/lpr mice, AICD was not induced, due to a lack of Fas
expression (Ref. 21 and Fig. 5
). However, TCR/CD9
stimulation-associated apoptosis occurred in MRL/lpr T cells
irrespective of the presence of anti-FasL mAb (Fig. 5
). Taken
together, these results indicate that apoptosis in TCR/CD9-costimulated
T cells is induced independently of Fas.

View larger version (19K):
[in this window]
[in a new window]
|
FIGURE 4. Differential, preventive effects of anti-FasL mAb on AICD vs
TCR/CD9-costimulation-associated apoptosis. Purified T cells were
stimulated with anti-CD3/anti-CD9 in the presence of control
mouse IgG or anti-FasL mAb (10 µg/ml) for 2 days. Activated T
cells (Con A stimulation IL-2 maintenance) were stimulated with
anti-CD3 in the presence of Ab for 24 h. Cells were harvested
and stained with PI. The proportion of hypodiploid (apoptotic) cells in
each group is indicated. The results are representative of three
similar experiments.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
FIGURE 5. Induction of apoptosis in TCR/CD9-costimulated T cells from
MRL/lpr mice. Purified T cells from 5-wk-old
MRL/lpr or MRL/+ mice were treated in a protocol that was
similar to the one used in Figure 4 . The results are representative of
two similar experiments.
|
|
Apoptosis associated with TCR/CD9 costimulation occurs
independently of the TNF pathway
Besides the Fas-FasL interaction, AICD has also been shown to
occur in T cells via the TNF pathway (29, 33). We examined whether TNF
is involved in TCR/CD9 costimulation-induced apoptosis (Fig. 6
). The addition of anti-TNF
polyclonal Ab (Fig. 6
A, Exp. 1) or anti-TNF mAb
(Fig. 6
, Exp. 2) alone or in combination with anti-FasL mAb only
resulted in a marginal prevention of apoptosis.

View larger version (26K):
[in this window]
[in a new window]
|
FIGURE 6. Apoptosis associated with TCR/CD9 costimulation is independent of the
TNF pathway. Purified B6 T cells were stimulated with
anti-CD3/anti-CD9 in the presence of indicated Abs for 2 days.
Exp. 1, polyclonal rabbit anti-TNF antiserum (1:50 dilution) and
anti-FasL mAb (10 µg/ml). Exp. 2, anti-TNF mAb (10 µg/ml),
anti-FasL mAb (10 µg/ml), and rIL-2 (100 U/ml).
|
|
Our previous study demonstrated that TCR/CD9 costimulation-induced
apoptosis is due to a defect in IL-2 production and is corrected by the
addition of exogenous IL-2 (24). This finding is shown in Figure 6
, Exp. 2. Together, TCR/CD9 costimulation-induced apoptosis is
independent of Fas and TNF pathways.
CPP32-like protease activity in TCR/CD9-stimulated, naive T cells
or TCR-restimulated, activated T cells
We measured CPP32-like protease activity in naive T cells
that were harvested at various hours after primary TCR/CD9 stimulation
or in activated T cells that were obtained at various hours after TCR
restimulation. Measurements were done in parallel to the detection of
the levels of apoptosis as measured by cell cycle analysis. Figure 7
shows that AICD reaches a peak as early
as 24 h after restimulation with anti-CD3, while apoptosis
after TCR/CD9 costimulation reaches maximal levels around 36 h
after primary stimulation of TCR and CD9. The CPP32-like protease
activity in both types of T cells harvested 0 to 36 h after
restimulation or primary stimulation is summarized in Figure 8
. In the AICD model, the CPP32-like
protease activity became detectable at 12 h after anti-CD3
restimulation and reached a peak level after 24 h. In contrast,
CPP32 activity was undetectable throughout the entire period (036 h)
of TCR/CD9 stimulation. The results suggest that the apoptosis due to
TCR/CD9 stimulation is independent of CPP32 activation.

View larger version (17K):
[in this window]
[in a new window]
|
FIGURE 7. Time course of cell death in two different apoptosis models. Purified T
cells or activated T cells were stimulated with
anti-CD3/anti-CD9 or anti-CD3, respectively, as described
in the legend of Figure 4 . The cells were harvested at the
indicated time points following mAb stimulation. The results are
representative of three similar experiments.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIGURE 8. Differential detection of CPP32 activity in TCR/CD9-costimulated, naive
T cells vs TCR-restimulated, activated T cells. Culturing was conducted
as described in Figure 4 . At the indicated time points, cytoplasmic
lysates were prepared, and the same amount of lysates (10 µg/sample)
were subjected to the CPP32-like protease assay as described in
Materials and Methods. The results are representative of
four similar experiments.
|
|
Peptide-based caspase inhibitors prevent both forms of apoptosis
Finally, we determined whether the peptide-based inhibitors that
are capable of blocking caspase-1 (ICE) and/or caspase-3 (CPP32)
activities affect the apoptosis induced in TCR/CD9-stimulated T cells
and TCR-restimulated T cells. Figure 9
shows that both types of apoptosis are largely prevented by two
different peptide-FMK caspase inhibitors. When the doses of these
inhibitors were titrated, we found that their efficacy to prevent
TCR/CD9 stimulation-associated apoptosis was comparable with their
efficacy to prevent AICD (Fig. 10
).
Taken together, TCR/CD9 stimulation-associated apoptosis requires some
members in the caspase family that are different from the caspase-3
(CPP32) subfamily proteases.

View larger version (17K):
[in this window]
[in a new window]
|
FIGURE 9. Addition of peptide-based caspase inhibitors protects T cells from both
TCR/CD9 costimulation-associated apoptosis and AICD. Culturing was
conducted as described in Figure 4 . A total of 50 µM Z-VAD-FMK,
BD-FMK, or ZFA-FMK (control) was included during the entire period (48
h) of stimulation of naive T cells with anti-CD3/anti-CD9 or
for 24 h following anti-CD3 stimulation of activated T cells.
The results are representative of four similar experiments.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIGURE 10. Titration of caspase inhibitors used for the prevention of apoptosis.
The doses for two types of caspase inhibitors were titrated in a
protocol of experiments that was similar to the one used in Figure 9 .
|
|
 |
Discussion
|
|---|
The results obtained in this study demonstrate that the
costimulation of CD9 as a non-CD28 costimulatory molecule during TCR
stimulation results in a potent activation of naive T cells, as
measured by [3H]TdR uptake, which is followed by
apoptosis instead of full activation (cellular proliferation). In
contrast to AICD, apoptosis in T cells that are activated based on such
an inappropriate costimulation is neither dependent upon Fas nor
associated with the activation of CPP32-like protease. Nevertheless,
this form of apoptosis is also prevented by two different peptide-based
caspase inhibitors. These observations indicate that two types of T
cell activation-associated apoptosis (AICD vs TCR/CD9
stimulation-induced cell death) differ in the involvement of the
pathway from Fas stimulation to CPP32 activation. The results also
suggest that TCR/CD9 stimulation-associated apoptosis involves the
participation of caspase family member(s) that are different from CPP32
but still sensitive to two representative caspase inhibitors, Z-VAD-FMK
and BD-FMK.
It has been established that T cells undergo apoptotic death as a
consequence of repeated stimulation (14, 15, 16). This form of apoptosis,
called AICD, occurs due to the interaction of Fas with FasL, both of
which are expressed on activated T cells (17, 18, 19). AICD is thought to
represent a homeostatic mechanism for controlling the number of
Ag-stimulated T cells. A recent study by Van Parijs et al. (21) has
shown that TCR-stimulated naive T cells undergo apoptotic death
when they are not given a CD28-mediated costimulus simultaneously.
Namely, the stimulation of T cells from TCR-transgenic mice with the
relevant peptide Ag plus paraformaldehyde-fixed APCs which lack
costimulatory activity fails to induce activation as measured by
[3H]TdR incorporation; rather, this type of stimulation
results in the induction of apoptosis. This type of apoptosis, termed
programmed cell death (PCD), was found to be independent of Fas and to
be corrected by the introduction CD28 costimulation (21).
The present form of apoptosis resulting from TCR/CD9 costimulation
differs from AICD but appears to resemble the aforementioned PCD.
However, there are substantial differences between PCD and apoptosis in
our model. PCD occurs as a failure of the activation of naive T cells;
in our model, naive T cells are strongly activated by TCR/CD9
costimulation, as observed by blast transformation (24) and levels of
[3H]TdR uptake that are comparable with those in CD28
costimulation (Fig. 1
and Refs. 23 and 24). Moreover, IL-2R is hardly
induced by TCR stimulation alone, whereas most of the
TCR/CD9-stimulated T cells express high levels of IL-2R (24). This
finding is consistent with the idea that naive T cells are previously
activated by TCR/CD9 costimulation. Therefore, the present form of
apoptosis is regarded as an inappropriate costimulation-induced cell
death. Our results also show that high levels of Fas are expressed on
TCR/CD9-costimulated naive T cells. Despite the expression of Fas, our
results indicate that, unlike AICD but similar to PCD, the present form
of apoptosis is independent of Fas. This conclusion is based on the
finding that TCR/CD9 stimulation-associated apoptosis is observed in
MRL/lpr T cells, is not blocked by anti-FasL mAb, and is
induced even when Fas expression is completely down-regulated by
NAC.
Inhibitors of either caspase-1 (ICE) or caspase-3 (CPP32) block
Fas-induced apoptosis, which suggests that both subfamilies of caspases
are involved in Fas-mediated apoptosis (20, 34, 35). The activation of
caspase-3 is dependent upon the activation of a caspase-1 (5),
indicating that these proteases are sequentially activated. Thus, a
representative death-pathway is formed from Fas through caspase-1 to
caspase-3. AICD uses this Fas-CPP32 (caspase-3) protease pathway (5, 6, 20). In contrast, neither Fas nor CPP32 appears to be involved in the
present form of apoptosis. While Fas-independent apoptosis appears to
occur in the aforementioned PCD (21), little is known regarding CPP32
activation-independent apoptosis.
Recent studies have revealed the complexity regarding the relationship
between CPP32 activation and apoptosis induction (34, 35, 36). Miossec et
al. (36) observed that CPP32 activation through precursor processing
can occur in situations in which T cells are activated but are not
undergoing apoptosis. This processing was associated with the detection
of CPP32-like protease activity. CPP32 activation that is not
associated with apoptosis may be explained by more recent observations
that apoptosis is inhibited by suppressing the activation of proteases
that function downstream of CPP32 (37, 38). Thus, CPP32 activation and
apoptosis induction are not necessarily associated. Our present results
show the induction of apoptosis in T cells that are not expressing
CPP32. These results may provide evidence for another line of
dissociation between CPP32 activation and apoptosis induction.
Although it is unlikely that CPP32-like protease activity is involved
in the apoptosis of TCR/CD9-costimulated naive T cells, this form of
apoptosis is blocked by two different peptide-based caspase inhibitors,
Z-VAD-FMK and BD-FMK. Z-VAD-FMK and BD-FMK are potent and weak
inhibitors, respectively, for caspase-1 (ICE) (22). CPP32 activity was
found to be blocked by these two inhibitors in the previous study (22)
and in the present in vitro assay for CPP32-like protease activity (our
unpublished observations), although the efficacy of these reagents to
block CPP32 appeared to be significantly lower compared with that of
DEVD-FMK (22). The fact that the apoptosis of T cell lines due to IL-2
withdrawal can be prevented by BD-FMK but not by Z-VAD-FMK (22)
suggests that this type of apoptosis does not use a caspase cascade
from caspase-1 (ICE) to caspase-3 (CPP32). Likewise, it is possible
that Z-VAD-FMK and BD-FMK, especially the latter inhibitor, prevent the
present form of apoptosis through an inhibition of the activity of
caspase(s) other than CPP32. This postulation is based on the
observations of others: The disruption of the CPP32 gene prevented
apoptosis in some but not many cell types (39), indicating the
dispensable role of CPP32 in most cell types. Consistent with this,
caspases other than CPP32 can also cleave poly(ADP-ribose) polymerase
and are sensitive to CPP32 inhibitors (40).
Our results illustrate that the apoptosis of naive T cells which is
induced as a result of inappropriate costimulation during primary T
cell activation exhibits different molecular features from those
observed in AICD. This form of apoptosis is not dependent on Fas
stimulation or on CPP32 activation. Nevertheless, the apoptosis is
prevented by peptide-based inhibitors that are capable of blocking the
caspase family members, including caspase-1 and caspase-3. Considering
that caspases other than CPP32 can also be blocked by CPP32 inhibitors
(40), these observations strongly suggest the involvement of the thus
far unidentified caspase cascade in the present form of apoptosis.
Thus, the current study could provide a model for investigating the
molecular mechanisms underlying the induction of apoptosis by a pathway
different from the Fas-CPP32 death pathway.
 |
Acknowledgments
|
|---|
We thank Tomoko Katsuta and Mari Yoneyama for secretarial
assistance.
 |
Footnotes
|
|---|
1 This work was supported by grants-in-aid for scientific research from the Ministry of Education, Science and Culture, Japan. 
2 Address correspondence and reprint requests to Dr. Hiromi Fujiwara, Biomedical Research Center, Osaka University Medical School, 2-2, Yamada-oka, Suita, Osaka 565, Japan. 
3 Abbreviations used in this paper: AICD, activation-induced cell death; FasL, Fas ligand; ICE, IL-1ß-converting enzyme; FMK, fluoromethyl ketone; NAC, N-acetyl-L-cysteine; MCA, (7-methoxycoumarin-4-yl)-acetyl; PI, propidium iodide; PCD, programmed cell death. 
Received for publication November 24, 1997.
Accepted for publication February 12, 1998.
 |
References
|
|---|
-
Henkart, P. A.. 1996. ICE family proteases: mediators of all apoptotic cell death?. Immunity 4:195.[Medline]
-
Nicholson, D. W.. 1996. ICE/CED-3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat. Biotechol. 14:297.[Medline]
-
Nagata, S.. 1997. Apoptosis by death factor. Cell 88:355.[Medline]
-
Darmon, A. J., D. W. Nicholson, R. C. Bleackley. 1995. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377:446.[Medline]
-
Enari, M., R. V. Talanian, W. W. Wong, S. Nagata. 1996. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380:723.[Medline]
-
Schlegel, J., I. Peters, S. Orrenius, D. K. Miller, N. A. Thornberry, T. T. Yamin, D. W. Nicholson. 1996. CPP32/apopain is a key interleukin 1ß-converting enzyme-like protease involved in Fas-mediated apoptosis. J. Biol. Chem. 271:1841.[Abstract/Free Full Text]
-
Erhardt, P., G. M. Cooper. 1996. Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL. J. Biol. Chem. 271:17601.[Abstract/Free Full Text]
-
Stefanis, L., D. S. Park, C. Y. I. Yan, S. E. Farinelli, C. M. Troy, M. L. Shelanski, L. A. Greene. 1996. Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support. J. Biol. Chem. 271:30663.[Abstract/Free Full Text]
-
Nicholson, D. W., A. Ali, N. A. Thornberry, J. P. Vaillancourt, C. K. Ding, M. Gallant, Y. Gareau, P. R. Griffin, M. Labelle, Y. A. Lazebnik, N. A. Munday, S. M. Raju, et al 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37.[Medline]
-
Tewari, M., L. T. Quan, K. ORourke, S. Desnoyers, Z. Zeng, D. R. Beidler, G. G. Poirier, G. S. Salvesen, V. M. Dixit. 1995. Yama/CPP32 ß, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801.[Medline]
-
Casciola-Rosen, L., D. W. Nicholson, T. Chong, K. R. Rowan, N. A. Thornberry, D. K. Miller, A. Rosen. 1996. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J. Exp. Med. 183:1957.[Abstract/Free Full Text]
-
Han, Z., N. Malik, T. Carter, W. H. Reeves, J. H. Wyche, E. A. Hendrickson. 1996. DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease. J. Biol. Chem. 271:25035.[Abstract/Free Full Text]
-
Steller, H.. 1995. Mechanisms and genes of cellular suicide. Science 267:1445.[Abstract/Free Full Text]
-
Cohen, J. J., R. C. Duke, V. A. Fadok, K. S. Sellins. 1992. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10:267.[Medline]
-
Green, D. R., D. W. Scott. 1994. Activation-induced apoptosis in lymphocytes. Curr. Opin. Immunol. 6:476.[Medline]
-
Russell, J. H.. 1995. Activation-induced death of mature T cells in the regulation of immune responses. Curr. Opin. Immunol. 7:382.[Medline]
-
Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, D. R. Green. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.[Medline]
-
Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438.[Medline]
-
Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D. H. Sherr, B. Z. Stanger, A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444.[Medline]
-
Los, M., M. Van de Craen, L. C. Penning, H. Schenk, M. Westendorp, P. A. Baeuerle, W. Droge, P. H. Krammer, W. Fiers, K. Schulze-Osthoff. 1995. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375:81.[Medline]
-
Van Parijs, L., A. Ibraghimov, A. K. Abbas. 1996. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4:321.[Medline]
-
Sarin, A., M. L. Wu, P. A. Henkart. 1996. Different interleukin-1ß-converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J. Exp. Med. 184:2445.[Abstract/Free Full Text]
-
Tai, X. G., Y. Yashiro, R. Abe, K. Toyooka, C. R. Wood, J. Morris, A. Long, S. Ono, M. Kobayashi, T. Hamaoka, S. Neben, H. Fujiwara. 1996. A role for CD9 molecules in T cell activation. J. Exp. Med. 184:753.[Abstract/Free Full Text]
-
Tai, X. G., K. Toyo-oka, Y. Yashiro, R. Abe, C. S. Park, T. Hamaoka, M. Kobayashi, S. Neben, H. Fujiwara. 1997. CD9-mediated costimulation of TCR-triggered naive T cells leads to activation followed by apoptosis. J. Immunol. 159:3799.[Abstract]
-
Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84:1374.[Abstract/Free Full Text]
-
Kayagaki, N., N. Yamaguchi, F. Nagao, S. Matsuo, H. Maeda, K. Okumura, H. Yagita. 1997. Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. USA 94:3914.[Abstract/Free Full Text]
-
Ozato, K., N. M. Mayer, D. H. Sachs. 1982. Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation 34:113.[Medline]
-
Horgan, K. J., G. A. Van Seventer, Y. Shimizu, S. Shaw. 1990. Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor-mediated stimuli but augmentation of responses by co-stimuli. Eur. J. Immunol. 20:1111.[Medline]
-
Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348.[Medline]
-
Telford, W. G., L. E. King, P. J. Fraker. 1992. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 13:137.[Medline]
-
Gottschalk, A. R., L. H. Boise, C. B. Thompson, J. Quintans. 1994. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. Natl. Acad. Sci. USA 91:7350.[Abstract/Free Full Text]
-
Delneste, Y., P. Jeannin, E. Sebille, J. P. Aubry, J. Y. Bonnefoy. 1996. Thiols prevent Fas (CD95)-mediated T cell apoptosis by down-regulating membrane Fas expression. Eur. J. Immunol. 26:2981.[Medline]
-
Sytwu, H. K., R. S. Liblau, H. O. McDevitt. 1996. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5:17.[Medline]
-
Enari, M., H. Hug, S. Nagata. 1995. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78.[Medline]
-
Tewari, M., V. M. Dixit. 1995. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270:3255.[Abstract/Free Full Text]
-
Miossec, C., V. Dutilleul, F. Fassy, A. Diu-Hercend. 1997. Evidence for CPP32 activation in the absence of apoptosis during T lymphocyte stimulation. J. Biol. Chem. 272:13459.[Abstract/Free Full Text]
-
Liu, X., H. Zou, C. Slaughter, X. Wang. 1997. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175.[Medline]
-
Wright, S. C., U. Schellenberger, H. Wang, D. H. Kinder, J. W. Talhouk, J. W. Larrick. 1997. Activation of CPP32-like proteases is not sufficient to trigger apoptosis: inhibition of apoptosis by agents that suppress activation of AP24, but not CPP32-like activity. J. Exp. Med. 186:1107.[Abstract/Free Full Text]
-
Kuida, K., T. S. Zheng, S. Na, C. Kuan, D. Yang, H. Karasuyama, P. Rakic, R. A. Flavell. 1996. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384:368.[Medline]
-
Gu, Y., C. Sarnecki, R. A. Aldape, D. J. Livingston, M. S. Su. 1995. Cleavage of poly(ADP-ribose) polymerase by interleukin-1ß-converting enzyme and its homologs TX and Nedd-2. J. Biol. Chem. 270:18715.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
S. Brouard, E. Mansfield, C. Braud, L. Li, M. Giral, S.-c. Hsieh, D. Baeten, M. Zhang, J. Ashton-Chess, C. Braudeau, et al.
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance
PNAS,
September 25, 2007;
104(39):
15448 - 15453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Pfistershammer, O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P. Steinberger, and W. Knapp
CD63 as an Activation-Linked T Cell Costimulatory Element
J. Immunol.,
November 15, 2004;
173(10):
6000 - 6008.
[Abstract]
[Full Text]
[PDF]
|
 |
|